Cerebral vein/venous sinus thrombosis with thrombocytopenia syndrome after COVID-19 vaccination

3Citations
Citations of this article
33Readers
Mendeley users who have this article in their library.

Abstract

Vaccines are important in managing the COVID-19 pandemic caused by SARS-CoV-2. Despite the very low incidence, severe cases of thrombosis with thrombocytopenia after COVID-19 vaccination termed as Thrombosis with Thrombocytopenia Syndrome (TTS) have been reported. TTS clinically resembles autoimmune heparin-induced thrombocytopenia. TTS can cause disability and even death. It usually presents 4-28 days after vaccination characterized by thrombocytopenia and progressive thrombosis, often causing cerebral vein/venous thrombosis (CVT) and splanchnic venous thrombosis. We should avoid all forms of heparin and platelet transfusion. While awaiting further information on the pathophysiological mechanism and treatment of TTS, clinicians should be aware of TTS with CVT in patients receiving COVID-19 vaccinations. This new syndrome of TTS is an active area of investigation globally. Here, we review the available literature.

Cite

CITATION STYLE

APA

Kawano, H., Hashimoto, Y., & Hirano, T. (2021). Cerebral vein/venous sinus thrombosis with thrombocytopenia syndrome after COVID-19 vaccination. Clinical Neurology, 61(9), 594–601. https://doi.org/10.5692/clinicalneurol.cn-001646

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free